GB9626864D0 - Vaccine - Google Patents

Vaccine

Info

Publication number
GB9626864D0
GB9626864D0 GBGB9626864.4A GB9626864A GB9626864D0 GB 9626864 D0 GB9626864 D0 GB 9626864D0 GB 9626864 A GB9626864 A GB 9626864A GB 9626864 D0 GB9626864 D0 GB 9626864D0
Authority
GB
United Kingdom
Prior art keywords
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9626864.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to GBGB9626864.4A priority Critical patent/GB9626864D0/en
Publication of GB9626864D0 publication Critical patent/GB9626864D0/en
Priority to CA002275896A priority patent/CA2275896A1/en
Priority to EP97953919A priority patent/EP0948352A1/en
Priority to JP52842398A priority patent/JP2001507004A/en
Priority to PCT/EP1997/007282 priority patent/WO1998028005A1/en
Priority to AU57639/98A priority patent/AU5763998A/en
Priority to ARP970106145A priority patent/AR011047A1/en
Priority to ZA9711565A priority patent/ZA9711565B/en
Priority to CO97074927A priority patent/CO4650187A1/en
Priority to US11/088,301 priority patent/US20050208123A1/en
Priority to US11/926,696 priority patent/US20080102112A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB9626864.4A 1995-04-03 1996-12-24 Vaccine Pending GB9626864D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB9626864.4A GB9626864D0 (en) 1996-12-24 1996-12-24 Vaccine
AU57639/98A AU5763998A (en) 1996-12-24 1997-12-22 Chlamydia vaccines
PCT/EP1997/007282 WO1998028005A1 (en) 1996-12-24 1997-12-22 Chlamydia vaccines
EP97953919A EP0948352A1 (en) 1996-12-24 1997-12-22 Chlamydia vaccines
JP52842398A JP2001507004A (en) 1996-12-24 1997-12-22 Chlamydia vaccine
CA002275896A CA2275896A1 (en) 1996-12-24 1997-12-22 Chlamydia vaccines
ARP970106145A AR011047A1 (en) 1996-12-24 1997-12-23 VACCINES TO PREVENT INFECTIONS PRODUCED BY CHLAMYDIA TRACHOMATIS, PROCEDURE TO OBTAIN THEM AND USE OF MUCOSAL ADJUVANTS COMBINED WITH MAJOR LAPROTEIN OF THE CHLAMYDIA TRACHOMATIS DIAPHRAGM IN THE MANUFACTURING
ZA9711565A ZA9711565B (en) 1996-12-24 1997-12-23 Vaccine
CO97074927A CO4650187A1 (en) 1996-12-24 1997-12-24 VACCINE COMPOSITION FOR THE PREVENTION OF INFECTIONS CAUSED BY CHLAMYDIA INCLUDING THE MAIN PROTEIN OF THE EXTERNAL MEMBRANE OF CHLAMYDIA COMBINED WITH A TERMOLABIL MUTATED ENTEROTOXIN FROM E.coli
US11/088,301 US20050208123A1 (en) 1995-04-03 2005-03-24 Chylamydia vaccine
US11/926,696 US20080102112A1 (en) 1995-04-03 2007-10-29 Chlamydia vaccines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9626864.4A GB9626864D0 (en) 1996-12-24 1996-12-24 Vaccine

Publications (1)

Publication Number Publication Date
GB9626864D0 true GB9626864D0 (en) 1997-02-12

Family

ID=10805014

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9626864.4A Pending GB9626864D0 (en) 1995-04-03 1996-12-24 Vaccine

Country Status (9)

Country Link
EP (1) EP0948352A1 (en)
JP (1) JP2001507004A (en)
AR (1) AR011047A1 (en)
AU (1) AU5763998A (en)
CA (1) CA2275896A1 (en)
CO (1) CO4650187A1 (en)
GB (1) GB9626864D0 (en)
WO (1) WO1998028005A1 (en)
ZA (1) ZA9711565B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1486215A3 (en) * 1997-03-21 2006-04-12 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US5962636A (en) * 1998-08-12 1999-10-05 Amgen Canada Inc. Peptides capable of modulating inflammatory heart disease
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
EP1216303A1 (en) * 1999-09-15 2002-06-26 Mogam Biotechnology Research Institute Novel detoxified mutants of escherichia coli heat-labile enterotoxin
PT1812058E (en) * 2004-10-25 2012-09-17 Statens Seruminstitut Chlamydia trachomatis antigens for vaccine and diagnostic use
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
US20090022755A1 (en) * 2005-03-31 2009-01-22 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
ES2788728T3 (en) 2010-05-28 2020-10-22 Spixia Biotechnology Ab Chimeric MOMP antigen, method and use
CA2976243C (en) 2015-02-10 2023-10-31 Ohio State Innovation Foundation Chlamydia-activated b cell platforms and methods thereof
CA3004924A1 (en) * 2015-11-10 2017-05-18 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
CN1173204A (en) * 1994-11-17 1998-02-11 马克西姆药物公司 Immunogens for stimulating mucosal immunity
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
FR2732605B1 (en) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc COMPOSITION FOR INDUCING MUCOSAL IMMUNE RESPONSE
NZ312502A (en) * 1995-07-07 1999-03-29 Oravax Inc Clostridium difficile toxins as mucosal adjuvants

Also Published As

Publication number Publication date
CO4650187A1 (en) 1998-09-03
AR011047A1 (en) 2000-08-02
EP0948352A1 (en) 1999-10-13
CA2275896A1 (en) 1998-07-02
JP2001507004A (en) 2001-05-29
ZA9711565B (en) 1998-08-27
WO1998028005A1 (en) 1998-07-02
AU5763998A (en) 1998-07-17

Similar Documents

Publication Publication Date Title
HUP9904549A3 (en) Vaccines
GB9712347D0 (en) Vaccine
GB9718901D0 (en) Vaccine
IL136447A0 (en) Vaccine
GB9711990D0 (en) Vaccine
GB9726555D0 (en) Vaccine
GB9720585D0 (en) Vaccine
EP0958373A4 (en) Vaccines
PL331424A1 (en) Antipaludian vaccine composition
GB9623233D0 (en) Vaccine composition
GB9626864D0 (en) Vaccine
GB9625968D0 (en) Vaccine
ZA982763B (en) Vaccines
GB9417880D0 (en) Vaccine
GB9609252D0 (en) Vaccines
GB9419969D0 (en) Vaccine
GB9625966D0 (en) Vaccine
GB9625967D0 (en) Vaccine
GB9604595D0 (en) Vaccines
GB9605229D0 (en) Vaccines
GB9604596D0 (en) Vaccines
GB9626882D0 (en) Vaccines
GB9614182D0 (en) Vaccines
GB9602617D0 (en) Vaccines
GB9606032D0 (en) Vaccines